Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference
Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria ; Development Candidate Selection Targeted for 2024 Expect...
Enanta Pharmaceuticals Inc Len Task Force Dr Decision Resources Exchange Commission Enanta Pharmaceuticals Chief Executive Officer
Source: marketscreener.com